Plastic Surgery Practice Valuation (2026 Benchmarks)

Plastic surgery remains an important segment of physician-services M&A, particularly for buyers seeking consumer-facing healthcare businesses with meaningful cash-pay and commercial-payor revenue. Compared with specialties that rely more heavily on Medicare or Medicaid reimbursement, plastic surgery can offer greater pricing flexibility and margin visibility, although valuation still varies based on procedure mix, payer mix, provider concentration, and the strength of the practice’s operating infrastructure.

Buyer interest continues to center on practices with diversified procedures, multiple providers, strong clinical leadership, and scalable ancillary services such as injectables, skincare, and medical-spa operations. These characteristics can position plastic-surgery practices between traditional physician-group valuations and higher-growth medical-aesthetics platforms, while creating additional opportunities for add-on acquisitions, cross-selling, and regional expansion.

What you will learn in this article:

• How 2025–2026 deal activity elevated plastic surgery into a top-quartile M&A category
• Standardized valuation ranges for platform vs add-on acquisitions
• How cash-pay aesthetics can lift multiples
• The operational and financial characteristics that buyers reward most
• Red flags and detractors that commonly compress valuation outcomes

2026 Valuation Benchmarks: Plastic Surgery

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Market Momentum: Plastic Surgery Transaction Trends

The plastic surgery specialty has emerged as one of the fastest-growing segments in physician M&A. According to the VMG Health 2025 M&A Report, plastic surgery transaction volume grew dramatically from just 5 deals in 2022 to 6 deals in 2023, then surged to 27 transactions in 2024, a 440% increase over the two-year period.

This acceleration places plastic surgery among the recent “large movers” in physician medical group consolidation, alongside cardiology. Private equity firms have increasingly shifted focus toward specialties where reimbursement risk can be mitigated through cash-pay procedures. Plastic surgery practices, particularly those with a robust aesthetic component, fit this profile perfectly.

The combination of insurance-based reconstructive procedures and elective cash-pay aesthetic services creates a diversified revenue model that appeals to buyers seeking margin stability and recession-resistant earnings.

Valuation Benchmarks: Where Plastic Surgery Practices Price

Plastic surgery practices straddle two adjacent valuation ranges depending on their revenue mix: traditional physician group multiples and medical spa/aesthetics multiples. Understanding where your practice falls on this spectrum is critical to setting realistic transaction expectations.

Traditional Physician Group Range

For plastic surgery practices operating primarily on insurance reimbursement (reconstructive procedures, post-mastectomy breast reconstruction, hand surgery, burn reconstruction), valuations generally follow physician medical group norms:

• Small groups (<$1M EBITDA): ~5×–6× EBITDA
• Mid-size groups ($1M–$3M EBITDA): ~5×–9× EBITDA
• Emerging platforms ($3M–$7M EBITDA): ~7×–11× EBITDA
• Established platforms ($7M+ EBITDA): ~9×–12×+ EBITDA

The $3 million EBITDA threshold remains a critical inflection point, shifting the buyer pool from “local add-on” to “platform-ready,” where multiples can increase by 2–4 turns.

Aesthetic/Cash-Pay Component Premium

Practices with significant aesthetic revenue (body contouring, facial rejuvenation, injectables, non-surgical procedures) can command slightly higher multiples:

• Small practices (<$1M EBITDA): ~3×–6× EBITDA
• Mid-size practices ($1M–$3M EBITDA): ~5×–8× EBITDA
• Scaled, multi-site operations ($3M+ EBITDA): ~7×–12× EBITDA
• Elite brands with multi-state footprint: 12×–15×+ EBITDA (rare outliers)

For plastic surgery practices that blend reconstructive and aesthetic services, the aesthetic revenue component can act as a multiple enhancer, adding 1–2 turns to what a purely insurance-based practice might command.

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Value Drivers: What Pushes Plastic Surgery Practices to the High End

Not all plastic surgery practices are the same. The following characteristics consistently drive premium multiples:

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Valuation Detractors: Common Discounts in Plastic Surgery Transactions

Just as specific characteristics drive premium multiples, certain red flags can depress valuations or eliminate buyer interest entirely:

• Single-Surgeon Concentration: 70%+ revenue from one surgeon adds succession and key person risk.
• Flat or Declining Case Volumes.
• Weak or Unvetted EBITDA Add-Backs.
• Heavy Medicaid or High Bad Debt: Although uncommon in plastic surgery, payer instability is consistently discounted across specialties.
• Compliance or Clinical Risk Flags: Licensure issues, inconsistent charting, or malpractice history immediately suppress multiples.
• Lack of Systems and Infrastructure.

The Platform Premium: Why Scale Matters in Plastic Surgery

One of the most significant valuation levers in plastic surgery M&A is the platform premium. Multiples do not necessarily rise linearly with EBITDA; they can step-change when buyers underwrite a platform with management and provider depth, infrastructure, and scalability. Investors are willing to pay more for larger assets with stability and growth potential.

Strategic investments in infrastructure, provider recruitment, or facility expansion can yield outsized returns by unlocking the next multiple tier.

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Payer Mix and Ancillaries: Common Levers That Can Move Your Multiple

Buyers’ price durability. The strength of your payer mix and the presence of high-margin ancillaries directly impact the multiple buyers will pay. For plastic surgery practices, the cash-pay aesthetic component and owned surgical facilities often deliver the highest “multiple elasticity”—the degree to which improving these factors lifts your valuation.

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Looking Ahead: Market Conditions and 2026 Outlook

Healthcare services M&A activity has cooled through 2025 and into 2026, particularly for physician practice management (PPM) transactions. According to PitchBook’s Q4 2025 Healthcare Services Report, overall healthcare services deal activity rose 9.6% year-over-year in 2025, even as PPM deal count fell approximately 18% for the year, driven by regulatory scrutiny in states such as California and reimbursement uncertainty. That softness persisted into 2026: PitchBook’s Q2 2026 Healthcare Services Report found healthcare services PE deal count down 18.5% year-over-year, with PPMs continuing to lag amid elevated interest rates and increased regulatory scrutiny.

That said, several signals point to a building recovery:

• Rising Exit Pressure: PPM exits jumped 57.1% in 2025, an early sign that sponsors are clearing aging holdings — a dynamic PitchBook flags as a potential catalyst for renewed transaction volume in 2026, particularly in oncology and musculoskeletal specialties.
• Physician Groups Gaining Relative Share: Despite the broader PPM slowdown, physician medical groups captured a record 46% share of Q1 2026 healthcare deal volume — up from 37% in Q1 2025 — with deal count up 18% year-over-year in that subsector, according to PwC’s Health Services US Deals 2026 Midyear Outlook.
• Continued Fragmentation: The physician medical group sector remains highly fragmented, providing ample acquisition targets for consolidators.

Preparing Your Practice for a Premium Valuation

Practice owners can invest in the following areas to help capture top-quartile pricing:

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Learn More

FOCUS Investment Banking specializes in maximizing transaction value for healthcare practice owners through our proven quarterback approach to M&A advisory.

If you’d like to learn more about our healthcare investment banking services, reach out to Eric Yetter or Andy Snyder.

Sources:

• VMG Health, “2025 Healthcare M&A Report,” VMG Health, December 2024
• Scope Research, “Healthcare M&A Valuation Report 2024,” Scope Research, December 2024